At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...

Difamilast demonstrated safety, efficacy in multiple eczema trials, joins crisaborole, rof ...

Merck Animal Health announced today the FDA approved atinvicitinib tablets (NUMELVI; Merck Animal Health), making it the first and only second-generation Janus kinase (JAK) inhibitor indicated for ...

Incyte’s decision to scrap work on its BET inhibitor program has not surprised analysts, who pointed to safety concerns overshadowing the drug class. The biopharma, which markets Novartis-partnered ...

Treatment approaches have shifted with the introduction of targeted agents, notably Bruton tyrosine kinase (BTK) inhibitors, as well as the emerging role of immunotherapy, according to a new review ...

The FDA accepted filing for a new drug application (NDA) today for tirabrutinib for the treatment of adults with relapsed or refractory primary central nervous system lymphoma (R/R PCNSL), according ...

Eli Lilly has axed its next-generation RET inhibitor. The Big Pharma pushed the candidate, LOXO-260, into the clinic to overcome acquired resistance to existing drugs such as its own Retevmo but has ...

Medically reviewed by Lindsay Cook, PharmD Key Takeaways JAK inhibitors can treat conditions like rheumatoid arthritis, cancer, and some skin and bowel diseases.Some JAK inhibitors have been shown to ...

In an interview with Targeted Oncology, Erin Crane, MD, MPH, discusses PARP inhibitor restrictions in gynecologic oncology.

PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for 2026 in patients with metabolic and fibrotic diseaseCarmel Nanthakumar, ...